Study of TVB 2640 in Subjects With Non-Alcoholic Steatohepatitis (NASH)
Status:
Completed
Trial end date:
2021-10-02
Target enrollment:
Participant gender:
Summary
This is a Phase 2 multi-center, randomized, single-blind, placebo-controlled study to
evaluate the safety and efficacy of TVB-2640 in subjects with non-alcoholic steatohepatitis
(NASH), a type of fatty liver disease. Subjects will be randomly assigned to 1 of 2 treatment
groups (TVB- 2640 at one of three doses or placebo). Following randomization, subjects will
begin the 12-week treatment period and will receive once daily TVB-2640 or placebo.